CANNABIS STRAINS
Born from Lawrence Ringo’s CBD pioneering work — Cannatonic crossed with Sour Tsunami — Canna-Tsu delivers 10–15% CBD alongside mild euphoria with minimal intoxication. One of the most medically relevant hybrids in the CBD lineage.
Canna-Tsu was developed within the Southern Humboldt Seed Collective by Lawrence Ringo, one of the most significant figures in the modern CBD breeding movement. Ringo spent years identifying naturally high-CBD phenotypes — a trait that had largely been bred out of the commercial cannabis gene pool in favour of high-THC varieties — and used selective breeding to stabilise CBD-dominant lines.
The parent strains — Cannatonic and Sour Tsunami — were themselves pioneering CBD cultivars. Cannatonic, bred by the Spanish collective Resin Seeds, introduced 1:1 CBD:THC ratios to the broader market. Sour Tsunami, one of Ringo’s own creations, was among the first strains to test reliably above 10% CBD in the USA. Crossing them in Canna-Tsu concentrated the CBD trait while introducing a more complex terpene profile and subtle hybrid vigor.
Lawrence Ringo passed away in 2014, but his genetic contributions — Sour Tsunami, Canna-Tsu, ACDC, and Harle-Tsu — became the foundation for the modern high-CBD market, including industrial hemp CBD cultivars that followed the 2018 US Farm Bill.
| Strain | Breeder / Origin | CBD% | THC% | Lineage Notes |
|---|---|---|---|---|
| Cannatonic | Resin Seeds (Spain) | 6–17% | 5–7% | MK Ultra × G13 Haze; pioneered 1:1 ratio |
| Sour Tsunami | Lawrence Ringo (SoHum) | 10–13% | 1–10% | Sour Diesel × NYC Diesel (CBD-selected) |
| Canna-Tsu | Ringo / SoHum Seed Collective | 10–15% | 5–10% | Cannatonic × Sour Tsunami |
| ACDC | Cannatonic phenotype | 14–20% | <1% | Cannatonic phenotypic selection; very high CBD:THC |
| Harle-Tsu | Ringo / SoHum | 21% | <1% | Harlequin × Sour Tsunami; highest-CBD Ringo line |
Unlike THC, which binds directly and potently to CB1 receptors in the brain (producing intoxication), CBD has a different and more complex pharmacological profile. Understanding these mechanisms explains why Canna-Tsu’s CBD-dominant ratio produces medical benefits without heavy psychoactivity.
CB2 Receptor Agonism: CBD engages CB2 receptors, which are concentrated in immune tissue and peripheral nervous system nodes. CB2 activation reduces pro-inflammatory cytokine release, contributing to Canna-Tsu’s anti-inflammatory applications.
5-HT1A Serotonin Receptor Agonism: CBD activates 5-HT1A receptors at higher concentrations, a mechanism shared with anxiolytic and antidepressant compounds. This pathway underpins CBD’s anti-anxiety effects and contributes to its potential in PTSD and generalised anxiety disorder.
TRPV1 Ion Channel Modulation: CBD acts as a TRPV1 agonist and desensitiser, a vanilloid receptor involved in pain signalling. This explains part of its analgesic activity, distinct from the opioid pathway.
CB1 Negative Allosteric Modulation: Perhaps most relevant to Canna-Tsu specifically, CBD acts as a negative allosteric modulator at CB1 receptors. It does not block THC from binding, but it reduces the efficiency of CB1 activation by THC, blunting psychoactive intensity. At a 2:1 CBD:THC ratio, this produces the characteristic “clear-headed” effect profile Canna-Tsu is known for.
| Ratio (CBD:THC) | Psychoactivity | Anxiety Risk | Medical Utility | Example Strains |
|---|---|---|---|---|
| 20:1+ | None / minimal | Very low | Epilepsy, child patients, hemp products | Charlotte’s Web, ACDC, Harle-Tsu |
| 4:1 | Very mild | Low | Anxiety, inflammation, neuropathy | Harlequin, Penelope |
| 2:1 | Mild, functional | Low | Anxiety, pain, PTSD, daytime use | Canna-Tsu, Cannatonic (CBD phenotypes) |
| 1:1 | Moderate, manageable | Low–moderate | Pain, MS, anxiety, sleep | Canna-Tsu (balanced phenos), Cannatonic |
| 1:4+ | Strong | Higher | Nausea, appetite, severe pain | Most recreational hybrids |
Canna-Tsu’s effect profile is defined by what it does not do as much as what it does. The high CBD content prevents the anxiety spike, racing thoughts, and overwhelming intoxication that high-THC strains can produce in sensitive consumers. What remains is a gentle, functional experience.
Onset (0–15 minutes): A mild mood lift and subtle sense of well-being. Muscle tension eases. Mild euphoria is present but unobtrusive — consumers consistently describe this phase as “taking the edge off” without impairment.
Main Effect Window (15–90 minutes): Clear-headed calm. Anxiety and stress relief without cognitive dulling. Pain perception decreases. Most consumers can remain functional — working, driving, or socialising — at standard doses, though individual tolerance to THC varies.
Comedown: Gradual, without the heavy sedation crash of high-THC indica strains. Some consumers report improved sleep quality when used in the evening, though this is primarily a daytime-friendly strain.
The earthy, sweet, citrus aroma — from the myrcene, pinene, and caryophyllene terpene combination — gives Canna-Tsu a pleasant, approachable smoking and vaporising experience compared to more pungent high-THC strains.
Canna-Tsu’s medical utility derives from its CBD:THC ratio and terpene synergy. The following table summarises the primary conditions reported by consumers and the relevant evidence quality for CBD’s activity in each.
| Condition | Relevant Mechanism | Evidence Quality | Notes |
|---|---|---|---|
| Anxiety | 5-HT1A agonism; CB1 modulation | Moderate (multiple RCTs) | Shannon 2019 case series; Bergamaschi 2011 SAD study |
| Chronic Inflammation | CB2 agonism; cytokine reduction | Moderate (animal + in vitro) | Strong preclinical evidence; human data limited |
| Neuropathic Pain | TRPV1; CB2; serotonin pathways | Moderate (Cochrane 2018) | 1:1 CBD:THC (Sativex) most studied in MS pain |
| Seizures (Epilepsy) | GABA modulation; sodium channels | High (Dravet/LGS RCTs; FDA approval) | Devinsky 2017 NEJM; evidence for isolate CBD (Epidiolex) |
| PTSD | Fear memory consolidation; sleep | Emerging (case reports, observational) | Elms 2019 open-label; mechanism theorised via amygdala modulation |
Important context: the medical evidence above relates primarily to isolated CBD or standardised CBD:THC preparations. Canna-Tsu as a whole-plant cultivar delivers a full terpene and cannabinoid spectrum that may enhance outcomes via the entourage effect (Russo 2011), but controlled trials of Canna-Tsu specifically do not exist. Patients managing serious conditions should consult a physician before using cannabis as a treatment strategy.
Canna-Tsu’s terpene profile inherits traits from both parent lines — the earthy-spice of Sour Tsunami’s Diesel heritage and the woody-sweet notes of Cannatonic’s Haze lineage. The result is a strain that smells more approachable than most high-CBD cultivars, which can trend toward grass or hay when terpenes are underdeveloped.
Myrcene (earthy, mango, clove): Contributes mild sedating quality and enhances cannabinoid absorption. As the most abundant terpene in most cannabis strains, myrcene provides Canna-Tsu’s characteristic base note.
Beta-Caryophyllene (spicy, peppery, woody): A CB2 receptor agonist, adding anti-inflammatory pharmacology to Canna-Tsu’s CBD-driven CB2 effects. The spice and pepper character comes through in the smoke and vapour.
Alpha-Pinene (pine, fresh, rosemary): Associated with bronchodilatory effects and, in cannabis research, with potential counteracting of THC-induced short-term memory impairment. The light citrus-herbal top note in Canna-Tsu’s aroma profile.
Canna-Tsu is a moderately sized hybrid that performs best in outdoor or greenhouse environments. The CBD-dominant trait is a recessive genetic expression that is environmentally sensitive — stress, heat, or nutrient imbalance can push phenotypes toward higher THC expression, so consistent cultivation conditions matter for pharmacological predictability.
| Parameter | Specification | Notes |
|---|---|---|
| Flowering Time | ~9 weeks (photoperiod) | Standard hybrid flowering window |
| Difficulty | Moderate | Requires consistent environment for CBD expression |
| Preferred Environment | Outdoor / greenhouse | Mediterranean-type climate optimal |
| Yield | Moderate | Not a high-yield commercial cultivar |
| Harvest Timing | Primarily cloudy trichomes | Early harvest preserves CBD:THC ratio; late harvest increases THC |
| pH (soil) | 6.0–7.0 | Standard cannabis soil range |
| Temperature | 18–26°C daytime | Avoid extremes to stabilise CBD expression |
One practical note for medical growers: have finished flower tested by a third-party laboratory if CBD:THC ratio precision matters. Phenotypic variation within Canna-Tsu is significant, and individual plants grown from seed can express ratios ranging from 1:1 to 3:1 CBD:THC. Clonal propagation from a verified high-CBD phenotype is the most reliable approach for consistency.